Genetics of Triglycerides and the Risk of Atherosclerosis

Current Atherosclerosis Reports

Volumn 19, Issue 7, 2017, Pages

  Dron, Jacqueline S ^a,b   Hegele, Robert A ^a,b  

^a WESTERN UNIVERSITY   (Canada)

^b ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

Complex trait; DNA sequencing; Genetic association; Mendelian randomization; Monogenic; Polygenic

Indexed keywords

ANGIOPOIETIN; ANGIOPOIETIN LIKE PROTEIN 3; ANGIOPOIETIN LIKE PROTEIN 4; APOLIPOPROTEIN A5; APOLIPOPROTEIN B; APOLIPOPROTEIN C3; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERMEDIATE DENSITY LIPOPROTEIN; LIPOPROTEIN LIPASE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ALLELE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL METABOLISM; DISEASE CLASSIFICATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; GENE IDENTIFICATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENETICS; GENOME-WIDE ASSOCIATION STUDY; HUMAN; HYPERLIPOPROTEINEMIA TYPE 1; HYPERTRIGLYCERIDEMIA; NONHUMAN; POPULATION RESEARCH; PREVALENCE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; BLOOD; COMPLICATION; GENETIC POLYMORPHISM; METABOLISM;

ATHEROSCLEROSIS; CHOLESTEROL, HDL; GENOME-WIDE ASSOCIATION STUDY; HUMANS; HYPERTRIGLYCERIDEMIA; POLYMORPHISM, GENETIC; TRIGLYCERIDES;

EID: 85020011219     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-017-0667-9     Document Type: Review

References (55)

1. Nordestgaard BG. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology. Circ Res. 2016;118(4):547–63.
2. Xiao C, Dash S, Morgantini C, Hegele RA, Lewis GF. Pharmacological targeting of the atherogenic dyslipidemia complex: the next frontier in CVD prevention beyond lowering LDL cholesterol. Diabetes. 2016;65(7):1767–78.
3. •• Reiner Z Hypertriglyceridaemia and risk of coronary artery disease. Nat Rev Cardiol. 2017. doi:10.1038/nrcardio.2017.31. A recent and comprehensive review on elevated TG levels and CAD risk.
4. Lewis GF, Xiao C, Hegele RA. Hypertriglyceridemia in the genomic era: a new paradigm. Endocr Rev. 2015;36(1):131–47.
5. Khera AV, Kathiresan S. Genetics of coronary artery disease: discovery, biology and clinical translation. Nat Rev Genet. 2017. doi:10.1038/nrg.2016.160.
6. Hegele RA, Ginsberg HN, Chapman MJ, Nordestgaard BG, Kuivenhoven JA, Averna M, et al. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol. 2014;2(8):655–66.
7. Varbo A, Benn M, Smith GD, Timpson NJ, Tybjaerg-Hansen A, Nordestgaard BG. Remnant cholesterol, low-density lipoprotein cholesterol, and blood pressure as mediators from obesity to ischemic heart disease. Circ Res. 2015;116(4):665–73.
8. Sniderman AD, Tremblay A, De Graaf J, Couture P. Phenotypes of hypertriglyceridemia caused by excess very-low-density lipoprotein. J Clin Lipidol. 2012;6(5):427–33.
9. Dash S, Xiao C, Morgantini C, Lewis GF. New insights into the regulation of chylomicron production. Annu Rev Nutr. 2015;35:265–94.
10. Connelly PW, Petrasovits A, Stachenko S, MacLean DR, Little JA, Chockalingam A. Prevalence of high plasma triglyceride combined with low HDL-C levels and its association with smoking, hypertension, obesity, diabetes, sedentariness and LDL-C levels in the Canadian population. Canadian heart health surveys Research group. Can J Cardiol. 1999;15(4):428–33.
11. Johansen CT, Kathiresan S, Hegele RA. Genetic determinants of plasma triglycerides. J Lipid Res. 2011;52(2):189–206.
12. Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European atherosclerosis society. Eur Heart J. 2013;34(45):3478–90a.
13. Brahm AJ, Hegele RA. Chylomicronaemia--current diagnosis and future therapies. Nat Rev Endocrinol. 2015;11(6):352–62.
14. Varbo A, Nordestgaard BG. Remnant cholesterol and triglyceride-rich lipoproteins in atherosclerosis progression and cardiovascular disease. Arterioscler Thromb Vasc Biol. 2016;36(11):2133–5.
15. Zilversmit DB. Atherogenic nature of triglycerides, postprandial lipidemia, and triglyceride-rich remnant lipoproteins. Clin Chem. 1995;41(1):153–8.
16. Chait A, Brunzell JD. Chylomicronemia syndrome. Adv Intern Med. 1992;37:249–73.
17. Johansen CT, Hegele RA. The complex genetic basis of plasma triglycerides. Curr Atheroscler Rep. 2012;14(3):227–34.
18. Dron JS, Hegele RA. Genetics of lipid and lipoprotein sisorders and traits. Curr Genet Med Rep. 2016;4(3):130–41.
19. Brahm A, Hegele RA. Hypertriglyceridemia. Nutrients. 2013;5(3):981–1001.
20. Gotoda T, Shirai K, Ohta T, Kobayashi J, Yokoyama S, Oikawa S, et al. Diagnosis and management of type I and type V hyperlipoproteinemia. J Atheroscler Thromb. 2012;19(1):1–12.
21. Young SG, Zechner R. Biochemistry and pathophysiology of intravascular and intracellular lipolysis. Genes Dev. 2013;27(5):459–84.
22. Rodrigues CE, Bonfa E, Carvalho JF. Review on anti-lipoprotein lipase antibodies. Clin Chim Acta. 2010;411(21–22):1603–5.
23. • Beigneux AP, Miyashita K, Ploug M, Blom DJ, Ai M, Linton MF, et al. Autoantibodies against GPIHBP1 as a cause of hypertriglyceridemia. N Engl J Med. 2017;376(17):1647–58. A recent finding that autoantibodies against GPIHBP1 can lead to chylomicronemia.
24. Surendran RP, Visser ME, Heemelaar S, Wang J, Peter J, Defesche JC, et al. Mutations in LPL, APOC2, APOA5, GPIHBP1 and LMF1 in patients with severe hypertriglyceridaemia. J Intern Med. 2012;272(2):185–96.
25. Johansen CT, Wang J, Lanktree MB, McIntyre AD, Ban MR, Martins RA, et al. An increased burden of common and rare lipid-associated risk alleles contributes to the phenotypic spectrum of hypertriglyceridemia. Arterioscler Thromb Vasc Biol. 2011;31(8):1916–26.
26. Johansen CT, Wang J, Lanktree MB, Cao H, McIntyre AD, Ban MR, et al. Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia. Nature Genet. 2010;42(8):684–7.
27. Johansen CT, Wang J, McIntyre AD, Martins RA, Ban MR, Lanktree MB, et al. Excess of rare variants in non-genome-wide association study candidate genes in patients with hypertriglyceridemia. Circ Cardio Genet. 2012;5(1):66–72.
28. Lee JH, Giannikopoulos P, Duncan SA, Wang J, Johansen CT, Brown JD, et al. The transcription factor cyclic AMP-responsive element-binding protein H regulates triglyceride metabolism. Nat Med. 2011;17(7):812–5.
29. Rees MG, Raimondo A, Wang J, Ban MR, Davis MI, Barrett A, et al. Inheritance of rare functional GCKR variants and their contribution to triglyceride levels in families. Hum Mol Gen. 2014;23(20):5570–8.
30. Wang J, Ban MR, Zou GY, Cao H, Lin T, Kennedy BA, et al. Polygenic determinants of severe hypertriglyceridemia. Hum Mol Gen. 2008;17(18):2894–9.
31. Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, Koseki M, et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature. 2010;466(7307):707–13.
32. Willer CJ, Schmidt EM, Sengupta S, Peloso GM, Gustafsson S, Kanoni S, et al. Discovery and refinement of loci associated with lipid levels. Nature Genet. 2013;45(11):1274–83.
33. Kuivenhoven JA, Hegele RA. Mining the genome for lipid genes. Biochem Biophys Acta. 2014;1842(10):1993–2009.
34. Rosenson RS, Najera SD, Hegele RA. Heterozygous familial hypercholesterolemia presenting as chylomicronemia syndrome. J Clin Lipidol. 2017;11(1):294–6.
35. Aljenedil S, Hegele RA, Genest J, Awan Z. Estrogen-associated severe hypertriglyceridemia with pancreatitis. J Clin Lipidol. 2017;11(1):297–300.
36. Hegele RA. Plasma lipoproteins: genetic influences and clinical implications. Nat Rev Genet. 2009;10(2):109–21.
37. Pollin TI, Damcott CM, Shen H, Ott SH, Shelton J, Horenstein RB, et al. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science. 2008;322(5908):1702–5.
38. Musunuru K, Pirruccello JP, Do R, Peloso GM, Guiducci C, Sougnez C, et al. Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. N Engl J Med. 2010;363(23):2220–7.
39. • Hegele RA. Multidimensional regulation of lipoprotein lipase: impact on biochemical and cardiovascular phenotypes. J Lipid Res. 2016;57(9):1601–7. A recent review on the primary genes involved in TG metabolism, and evidence between TG levels and atherosclerosis risk
40. Swerdlow DI, Kuchenbaecker KB, Shah S, Sofat R, Holmes MV, White J, et al. Selecting instruments for Mendelian randomization in the wake of genome-wide association studies. Int J Epidemiol. 2016;45(5):1600–16.
41. Do R, Willer CJ, Schmidt EM, Sengupta S, Gao C, Peloso GM, et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet. 2013;45(11):1345–52.
42. • Dewey FE, Gusarova V, O'Dushlaine C, Gottesman O, Trejos J, Hunt C, et al. Inactivating variants in ANGPTL4 and risk of coronary artery disease. N Engl J Med. 2016;374(12):1123–33. A recent study confirming the association between rare and common ANGPTL4 variants and low TG/high HDL-C and decreased CAD risk
43. • Stitziel NO, Stirrups KE, Masca NGD, Erdmann J. Coding variation in ANGPTL4, LPL, and SVEP1 and the risk of coronary disease. N Engl J Med. 2016;374(12):1134–44. A large-scale study confirming the association between two common LPL variants and high TG/low HDL-C with increased CAD risk.
44. • Helgadottir A, Gretarsdottir S, Thorleifsson G, Hjartarson E, Sigurdsson A, Magnusdottir A, et al. Variants with large effects on blood lipids and the role of cholesterol and triglycerides in coronary disease. Nature Genet. 2016;48(6):634–9. A study in Icelanders of several rare genetic variants, including ANGPTL4 variants, associated with TG and CAD risk, but also jointly associated with HDL-C and non-HDL-C
45. Do R, Stitziel NO, Won HH, Jorgensen AB, Duga S, Angelica Merlini P, et al. Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. Nature. 2015;518(7537):102–6.
46. Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybjaerg-Hansen A. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med. 2014;371(1):32–41.
47. Crosby J, Peloso GM, Auer PL, Crosslin DR, Stitziel NO, Lange LA, et al. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med. 2014;371(1):22–31.
48. • Nioi P, Sigurdsson A, Thorleifsson G, Helgason H, Agustsdottir AB, Norddahl GL, et al. Variant ASGR1 associated with a reduced risk of coronary artery disease. N Engl J Med. 2016;374(22):2131–41. Report of an association between an intronic deletion in ASGR1, a relatively recent gene implicated in TG levels, and CAD
49. Thomsen M, Varbo A, Tybjaerg-Hansen A, Nordestgaard BG. Low nonfasting triglycerides and reduced all-cause mortality: a mendelian randomization study. Clin Chem. 2014;60(5):737–46.
50. Khera AV, Won HH, Peloso GM, O'Dushlaine C, Liu D, Stitziel NO, et al. Association of rare and common variation in the lipoprotein lipase gene with coronary artery disease. JAMA. 2017;317(9):937–46.
51. Ng DS, Wong NC, Hegele RA. HDL--is it too big to fail? Nat Rev Endocrinol. 2013;9(5):308–12.
52. Hovingh GK, Rader DJ, Hegele RA. HDL re-examined. Curr Opin Lipidol. 2015;26(2):127–32.
53. Sarwar N, Sandhu MS, Ricketts SL, Butterworth AS, Di Angelantonio E, Boekholdt SM, et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet. 2010;375(9726):1634–9.
54. Drenos F, Talmud PJ, Casas JP, Smeeth L, Palmen J, Humphries SE, et al. Integrated associations of genotypes with multiple blood biomarkers linked to coronary heart disease risk. Hum Mol Gen. 2009;18(12):2305–16.
55. Stitziel NO, Khera AV, Wang X, Bierhals AJ, Vourakis AC, Sperry AE, et al. ANGPTL3 deficiency and protection against coronary artery disease. J Am Coll Cardiol. 2017;69(16):2054–63.